Seawolf Therapeutics 获 1 亿美元融资,并与赛诺菲达成 DNA 疗法合作
Big-name investors pour $100M into DNA therapeutics developer Seawolf
Seawolf Therapeutics 完成 1 亿美元融资并从隐身状态亮相,创始投资方 Versant Ventures 领投种子轮并参与 A 轮,礼来、CRISPR Therapeutics 和诺华的风投部门也参与其中。
Seawolf Therapeutics, a San Diego company with a cache of well-known life sciences investors, emerged from stealth on Monday, equipped with $100 million to support its research into DNA-based therapies.
Seawolf’s founding investor, Versant Ventures, led its seed funding and participated in a Series A round alongside other prominent biotechnology backers like MPM BioImpact, Alexandria Venture Investments and others. The financing also drew interest from fellow drug companies, with Eli Lilly, CRISPR Therapeutics and the venture arm of Novartis all contributing.
As part of its debut, Seawolf disclosed a partnership with French pharmaceutical giant Sanofi. Though sparse on details, the research collaboration and exclusive license agreement will be “multi-target,” and focus on developing therapies for bleeding disorders and additional unnamed indications. Seawolf could take home as much as $1.2 billion across various milestone payments, as well as tiered royalties on any resulting products.
“With a strong syndicate of investors and our collaboration with Sanofi, we are well-positioned to execute on our next stage of growth, which will include advancing our lead program for metabolic diseases and collaborating with Sanofi in its mission to develop therapies for patient unmet needs,” said Elizabeth Alcamo, Seawolf’s CEO, in a statement.
Seawolf is built around a technology that uses a protective casing of fat molecules — known as lipid nanoparticles, or LNPs for short — to deliver beneficial packages of genetic material into cells. Specifically, this “TRIDENT” platform takes DNA that’s been engineered to avoid triggering an immune system response and places it into a proprietary LNP.
That nanoparticle then, with help from an additional “auxiliary” component, shepherds the DNA into the nucleus, where it provides the instructions for making proteins that combat disease. Drugs made from this system share all the pros of RNA-based LNP therapies, according to Seawolf, but with the added benefit of longer-lasting expression.
The company claims that, in primate tests, medicines created with its technology were potent, durable and safe. And unlike technology platforms that use viruses to deliver DNA payloads, TRIDENT therapies can be redosed, offering “the ability to fine-tune or supplement dosing through repeated administration.”
“Nucleic acid-based therapies have advanced dramatically over the past decade,” said Tom Woiwode, a managing director at Versant and chair of Seawolf’s board, in a statement. The startup’s team is “now delivering on the promise of using DNA to drive robust and long-term expression of therapeutic proteins directly from the patient’s own cells.”
Seawolf said its system can be useful across a “broad range” of diseases, including both rare and prevalent ones, and that it worked as intended in both primate and mouse models of metabolic and rare diseases.
The company’s lead program goes after metabolic diseases — an area of venture capital investment that, as of late, has cooled a bit. So far this year, emerging drugmakers in this field have received about $740 million from 26 of the most prolific biotech venture firms, according to data compiled by BioPharma Dive. That’s down from the nearly $1.3 billion and $1.6 billion seen in 2025 and 2024, respectively.
来源:BioPharma Dive · biopharmadive.com